The prospective trial to validate the superior efficacy of sequential therapy to standard therapy in Helicobacter pylori eradication

Comparison of standard triple therapy and sequential therapy for Helicobacter pylori eradication in Korea

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0000014

Enrollment

348

Registered

2010-07-16

Start date

2009-08-19

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Patients are randomly allocated to receive a 10-day sequntial regimen (rabeprazole 20mg, amoxicillin 1.0g each administered twice daily for the first 5 days, followed by rabeprazole 20mg, clari

or standard therapy(rabeprazole 20mg, amoxicillin 1.0g, clarithromycin 500mg, each administered twice daily for 7 days). The eradication will be confirmed by urea breath test at 4 weeks after the last

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Ages between 18 and 85 2) Peptic ulcer(active or inactive) in endoscopy and positive for rapid urease test 3) No peptic ulcer in endoscopy but positive for rapid urease test, who want to eradicate the H.pylori 4) Participants who agree to participate in this study after informed consent

Exclusion criteria

Exclusion criteria: 1) Patients who refused to participate in this study 2) Paticipants with a history of treatment for H.pylori 3) Use of proton pump inhibitor, antibiotics, H2-receptor antagonists, or bismuth in the previous 2 weeks 4) Concomitant use of anticoagulants, aspirin or steroids 5) History of gastric resection including endoscopic mucosal resection 6) Combined severe cardiovascular, pulmonary or endocrine disorders 7) Serious hepatic or renal dysfunction 8) hematologic disorders 9) Any kinds of malignant diseases 10) pregnancy or lactation, women who were not willing to practice acceptable contraception

Design outcomes

Primary

Measure	Time frame
Eradication rate	—

Secondary

Measure	Time frame
Adverse effects	—

Countries

Korea, Republic of

Contacts

Public ContactSeong Woo Jeon

Kyungpook National University Hospital

Outcome results